Daiichi Sankyo Aims For Muscular Dystrophy Drug Development With New Orphan Disease Institute
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo to establish a new company, the Orphan Disease Treatment Institute, together with Innovation Network Corporation of Japan and Mitsubishi UFJ Capital, to develop drugs for Duchenne muscular dystrophy.